Dexcom Inc. reported an insider sale by a senior executive this week when Michael Jon Brown, the company’s Executive Vice President and Chief Legal Officer, disposed of 1,700 shares of company stock on April 15, 2026. The reported sale price was $63.04 per share, producing gross proceeds of $107,168, and the transaction was recorded in a Form 4 filing with the Securities and Exchange Commission on April 16, 2026.
The shares were sold through a pre-arranged 10b5-1 trading plan that Brown established on November 26, 2025. According to the company filing, the 10b5-1 plan permits orderly dispositions of shares owned by Brown, and the shares noted above were sold pursuant to that plan.
After this disposition, Brown’s direct holdings in Dexcom stand at 111,204 shares. That total includes 77,603 unvested Restricted Stock Units (RSUs). The filing breaks down the unvested RSUs by grant date and vesting schedule: 39,019 RSUs were granted on March 8, 2026 and vest through March 8, 2029; 19,948 RSUs were granted on March 8, 2025 and vest through March 8, 2028; 11,399 RSUs were granted on March 8, 2025 and vest through March 8, 2027; and 7,237 RSUs were granted on March 8, 2024 and vest through March 8, 2027.
At the time of the sale the stock changed hands at a price above the then-current market quote reported in the filing. The sale price of $63.04 exceeded the contemporaneous share price of $61.23. The filing notes that, despite this transaction price premium, Dexcom’s shares remained significantly below InvestingPro’s Fair Value estimate and were listed among the platform’s most undervalued stocks.
Financial and market context
Separately from the insider transaction, Dexcom disclosed financial and corporate developments that have been made public and highlighted by analysts. The company reported revenue of $1.26 billion, representing a 13% increase year-over-year, driven by new customer demand and ongoing sell-through into the first quarter of 2026. These results and forward expectations have prompted several firms to revisit ratings and price targets.
- Evercore ISI upgraded Dexcom to Outperform from In Line, assigning a $90 price target and citing expectations for sustained revenue growth and margin improvements through 2028.
- TD Cowen reiterated its Buy rating, emphasizing an outlook for margin expansion in 2026-2028.
- Canaccord Genuity maintained a Buy rating while lowering its price target to $95 from $99.
- Stifel also kept a Buy rating with an $85 price target, noting that Dexcom’s fourth-quarter results were in line with prior guidance.
In addition to analyst activity, the company announced a board appointment: Rick Osterloh, a Google executive with experience in platforms and devices, has joined Dexcom’s Board of Directors. The appointment was cited in public company disclosures as a corporate development of interest to investors.
Disclosure and reporting
The insider sale and the details of Brown’s holdings, including the RSU grant and vesting schedules, were disclosed in the Form 4 filing with the SEC dated April 16, 2026. The 10b5-1 trading plan under which the sale was executed is dated November 26, 2025, according to the filing.
Investors and market participants seeking additional valuation analysis and company performance context may refer to available research products cited by market platforms that monitor such equities. The company’s recent revenue figure and the analyst commentary noted above are part of the public record and were included in reporting accompanying the filing.
Summary
In short, Dexcom’s chief legal officer sold 1,700 shares under a previously established 10b5-1 plan, leaving him with 111,204 shares including a substantial portion of unvested RSUs with specified vesting timelines. The sale price was modestly above the market quote reported at the time but the stock remains noted as trading below a referenced fair value estimate. Concurrently, the company posted year-over-year revenue growth and drew a series of analyst rating actions and a board appointment that together contribute to the current investor landscape.